Hepion Pharmaceuticals

Hepion Pharmaceuticals 是一家在股票代码 HEPA (US) 下上市的公司。

涉及Hepion Pharmaceuticals的并购和融资。

• Hepion Pharmaceuticals and Pharma Two B have announced they will merge  (公布2024八月8号)..

查看带有其 5 名主要高管的组织结构图

Hepion Pharmaceuticals 搜索最多的简介

• John Brancaccio, Chairman of the Board
• Timothy Block, Director
• Kaouthar Lbiati, Director

高管在Hepion Pharmaceuticals变化

• John Cavan, Chief Financial Officer and Interim Chief Executive Officer, 已经离开公司  (新闻发布的2024八月8号).
• Michael Purcell已作为Director加入公司  (新闻发布的2024三月7号).

创建提醒
跟踪 Hepion Pharmaceuticals 的高管变动

Hepion Pharmaceuticals 拥有 1,837 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。

Popular M&A news in 药店

• Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
• Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
• Lundbeck has announced the acquisition of Longboard Pharmaceuticals  (公布2024十月17号).

药店 行业的其他推荐联系人

• Sanofi 企业 Julie Van Ongevalle - Executive Vice President and Head of Consumer Healthcare
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board
• Braeburn Pharmaceuticals 企业 Seth Harrison - Chairman and Director

了解更多有关药店行业的信息 >

Hepion Pharmaceuticals 的最新新闻稿

• Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger – Hepion Pharmaceuticals
• Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds – Hepion Pharmaceuticals
• Hepion Pharmaceuticals to Present at NASH-TAG 2024 – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes – Hepion Pharmaceuticals
• Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit – Hepion Pharmaceuticals
• Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat – Hepion Pharmaceuticals
• Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model – Hepion Pharmaceuticals
• View more press releases Close

关于 Hepion Pharmaceuticals 的社交媒体

• Hepion Pharmaceuticals 在 维基百科、谷歌新闻 和 雅虎财经
• Hepion Pharmaceuticals 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Kaouthar Lbiati

致电Hepion Pharmaceuticals，电话：+1 212...

查看组织结构图

Register to receive your alert

报告错误